l General Information |
Product Name | Rosiglitazone |
General description | Rosiglitazone is an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. |
Synonym | BRL 49653 |
Purity | ≥98.0%(HPLC) | CAS Number | 122320-73-4 |
Formula | C18H19N3O3S | Molecular Weight | 357.43 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25°C) | DMSO | ≥50mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | When rosiglitazone is used as monotherapy, it is associated with increases in total cholesterol, LDL, and HDL. It is also associated with decreases in free fatty acids. Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not
for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
